PL378437A1 - Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń - Google Patents

Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Info

Publication number: PL378437A1
Authority: PL; Poland
Prior art keywords: cyclohexanecarbonyl; ylmethoxy; oxazol; atherosclerosis; diabetes
Prior art date: 2003-02-27

Application number

PL378437A

Other languages

English (en)

Inventor

Christian Stapper

Heiner Glombik

Eugen Falk

Jochen Goerlitzer

Dirk Gretzke

Stefanie Keil

Hans-Ludwig Schaefer

Wolfgang Wendler

Original Assignee

Sanofi-Aventis Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-19

Publication date

2006-04-03

2004-02-19 Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh

2006-04-03 Publication of PL378437A1 publication Critical patent/PL378437A1/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

PL378437A 2003-02-27 2004-02-19 Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń PL378437A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number	Publication Date
PL378437A1 true PL378437A1 (pl)	2006-04-03

Family

ID=32920629

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL377735A PL377735A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL378437A PL378437A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL378130A PL378130A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL377735A PL377735A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL378130A PL378130A1 (pl)	2003-02-27	2004-02-19	Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Country Status (34)

Country	Link
US (5)	US7335671B2 (pl)
EP (3)	EP1599455B1 (pl)
JP (3)	JP2006519193A (pl)
KR (3)	KR20050105492A (pl)
CN (3)	CN100439347C (pl)
AR (3)	AR043432A1 (pl)
AT (3)	ATE430738T1 (pl)
AU (3)	AU2004215672B2 (pl)
BR (3)	BRPI0407758A (pl)
CA (3)	CA2517386A1 (pl)
CL (2)	CL2004000391A1 (pl)
CO (2)	CO5690578A2 (pl)
DE (4)	DE10308355A1 (pl)
DK (3)	DK1599452T3 (pl)
EC (2)	ECSP055986A (pl)
ES (3)	ES2326418T3 (pl)
HR (3)	HRP20050744A2 (pl)
IL (2)	IL170316A (pl)
MA (3)	MA27736A1 (pl)
MX (3)	MXPA05008951A (pl)
NO (3)	NO20054398L (pl)
OA (2)	OA13035A (pl)
PA (1)	PA8596801A1 (pl)
PE (3)	PE20040959A1 (pl)
PL (3)	PL377735A1 (pl)
PT (3)	PT1599452E (pl)
RS (1)	RS20050594A (pl)
RU (3)	RU2005129995A (pl)
SA (1)	SA04250153A (pl)
TN (2)	TNSN05204A1 (pl)
TW (3)	TW200508210A (pl)
UY (2)	UY28210A1 (pl)
WO (3)	WO2004076427A1 (pl)
ZA (2)	ZA200505765B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en)	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) *	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de)	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de)	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de)	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
WO2007039177A2 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2006347121B2 (en)	2006-08-10	2013-06-06	Acacia-No-Ki Co., Ltd.	Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia
CN101801906A (zh)	2007-08-16	2010-08-11	索尔维公司	制备4-氟取代的3-氧代-烷酸酯的方法
PT2246343T (pt)	2008-02-29	2016-08-05	Nissan Chemical Ind Ltd	Processo de produção de composto de tiofeno e seu intermediário
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
ES2932091T3 (es)	2017-12-13	2023-01-11	Canon Kk	Cartucho y dispositivo de formación de imágenes
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) *	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en)	1996-01-17	1997-07-24	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP3149958B2 (ja)	1996-08-30	2001-03-26	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ―１誘導体
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
UA64713C2 (uk)	1996-12-31	2004-03-15	Reddys Lab Ltd Dr	Похідні азолідиндіону, спосіб їх одержання (варіанти), фармацевтичні композиції на їх основі, спосіб попередження або лікування, спосіб зниження рівня глюкози і проміжна сполука
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
KR20010021936A (ko)	1997-07-16	2001-03-15	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP4345230B2 (ja) *	1998-03-10	2009-10-14	小野薬品工業株式会社	カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (fr) *	1998-08-27	2000-03-09	Ono Pharmaceutical Co., Ltd.	Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de) *	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2002542245A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	置換イミダゾール、それらの製造および使用
US6908926B1 (en) *	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
HUP0200997A3 (en) *	1999-04-28	2003-03-28	Sanofi Aventis Deutschland	Tri-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
IL145922A0 (en)	1999-04-28	2002-07-25	Aventis Pharma Gmbh	Di-aryl acid derivatives as ppar receptor ligands
CA2371271A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
ES2265952T3 (es)	1999-06-18	2007-03-01	MERCK & CO., INC.	Derivados de ariltiazolidindiona y ariloxazolidindiona.
US6413737B1 (en)	1999-07-09	2002-07-02	Cohesion Technologies, Inc.	Ecarin prothrombin protease and methods
MXPA02000973A (es)	1999-07-29	2002-07-30	Lilly Co Eli	Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
KR20020033778A (ko) *	1999-09-01	2002-05-07	로버트 흐라이탁, 미쉘 베스트	설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
TW200514783A (en)	1999-09-22	2005-05-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
PL357118A1 (pl)	1999-12-03	2004-07-12	Astrazeneca Ab	Postać krystaliczna kwasu (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowego
WO2001072290A2 (en)	2000-03-31	2001-10-04	Probiodrug Ag	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
KR20030007548A (ko)	2000-04-25	2003-01-23	교린 세이야꾸 가부시키 가이샤	티아졸리딘디온 유도체의 신규한 안정한 결정 및 이의제조방법
CA2407538C (en)	2000-04-28	2007-01-09	Asahi Kasei Kabushiki Kaisha	Novel bicyclic compounds
AU2001259592B2 (en)	2000-05-11	2005-02-24	Bristol-Myers Squibb Co.	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
EP1289526A4 (en)	2000-05-30	2005-03-16	Merck & Co Inc	MELANOCORTIN RECEPTOR AGONISTS
CZ20024003A3 (cs) *	2000-06-09	2003-03-12	Aventis Pharma Deutschland Gmbh	Deriváty acylfenylmočoviny, způsoby jejich výroby a použití jako léčiva
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
DE60128239T2 (de) *	2000-08-23	2008-01-10	Eli Lilly And Co., Indianapolis	Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
DE60129712T2 (de)	2000-08-23	2008-07-03	Eli Lilly And Co., Indianapolis	Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
AU2002222573A1 (en)	2000-12-05	2002-06-18	Kyorin Pharmaceutical Co. Ltd.	Substituted carboxylic acid derivatives
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
ES2277890T3 (es)	2000-12-21	2007-08-01	Sanofi-Aventis Deutschland Gmbh	Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
MXPA03005763A (es) *	2000-12-25	2004-05-03	Ono Pharmaceutical Co	Compuestos derivados de dihidronaftaleno y agente que comprende el derivado como ingrediente activo.
JP2004529097A (ja) *	2001-02-15	2004-09-24	ファイザー・プロダクツ・インク	Ｐｐａｒアゴニスト
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CZ20033328A3 (cs) *	2001-06-07	2004-06-16	Eli Lilly And Company	Modulátory receptorů aktivovaných proliferátory peroxisomů (PPAR)
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003004458A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	New compounds
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
CA2458210C (en)	2001-08-31	2011-09-20	Aventis Pharma Deutschland Gmbh	Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar-activators
ATE433440T1 (de)	2002-02-05	2009-06-15	Lilly Co Eli	Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en)	2002-07-09	2004-01-23	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de active IP Right Grant
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Application Discontinuation
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de active Application Filing
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Application Discontinuation
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Application Discontinuation
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de active Application Filing
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 US US10/789,017 patent/US7335671B2/en not_active Expired - Lifetime
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 US US10/788,996 patent/US7259177B2/en active Active
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HRP20050744A2 (en)	2006-09-30
PE20050292A1 (es)	2005-05-24
ECSP055985A (es)	2006-01-16
DK1599452T3 (da)	2007-10-01
MXPA05008995A (es)	2005-10-18
EP1599455A1 (de)	2005-11-30
CN1753879A (zh)	2006-03-29
HRP20050742A2 (en)	2006-09-30
CL2004000391A1 (es)	2005-01-07
DE502004004139D1 (de)	2007-08-02
ZA200505765B (en)	2006-05-31
AU2004215673A1 (en)	2004-09-10
CL2004000392A1 (es)	2005-04-22
IL170314A (en)	2010-11-30
NO20054398L (no)	2005-11-02
MXPA05008951A (es)	2005-11-04
TW200508210A (en)	2005-03-01
US7872034B2 (en)	2011-01-18
JP2006519194A (ja)	2006-08-24
SA04250153A (ar)	2005-12-03
US20050215596A1 (en)	2005-09-29
PE20040959A1 (es)	2005-01-17
ATE435217T1 (de)	2009-07-15
CN1756748A (zh)	2006-04-05
EP1599453B1 (de)	2009-05-06
OA13035A (en)	2006-11-10
JP2006519193A (ja)	2006-08-24
KR20050105492A (ko)	2005-11-04
NO20054396D0 (no)	2005-09-22
PT1599453E (pt)	2009-07-14
CN100439347C (zh)	2008-12-03
DK1599455T3 (da)	2009-11-09
CO5690580A2 (es)	2006-10-31
KR20050106462A (ko)	2005-11-09
PT1599452E (pt)	2007-09-12
WO2004076427A1 (de)	2004-09-10
CN1753881A (zh)	2006-03-29
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16
CN100398526C (zh)	2008-07-02
ES2326418T3 (es)	2009-10-09
US20080015238A1 (en)	2008-01-17
AR043427A1 (es)	2005-07-27
US20040209920A1 (en)	2004-10-21
US7259177B2 (en)	2007-08-21
AU2004215673B2 (en)	2009-10-01
RU2005130002A (ru)	2006-01-27
MXPA05008988A (es)	2005-10-18
BRPI0407758A (pt)	2006-02-14
PT1599455E (pt)	2009-09-29
PL377735A1 (pl)	2006-02-20
EP1599455B1 (de)	2009-07-01
BRPI0407814A (pt)	2006-02-14
AU2004215677B2 (en)	2010-01-07
NO20054408D0 (no)	2005-09-22
CO5690578A2 (es)	2006-10-31
CA2517381A1 (en)	2004-09-10
CA2517386A1 (en)	2004-09-10
TNSN05206A1 (en)	2007-06-11
WO2004076426A1 (de)	2004-09-10
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
DE502004009453D1 (de)	2009-06-18
AU2004215672B2 (en)	2010-01-07
AR043432A1 (es)	2005-07-27
CA2516620A1 (en)	2004-09-10
EP1599453A1 (de)	2005-11-30
US7335671B2 (en)	2008-02-26
BRPI0407907A (pt)	2006-02-14
ATE365159T1 (de)	2007-07-15
JP2006519199A (ja)	2006-08-24
WO2004076428A1 (de)	2004-09-10
PE20050293A1 (es)	2005-05-24
DE10308355A1 (de)	2004-12-23
ES2329366T3 (es)	2009-11-25
NO20054398D0 (no)	2005-09-22
AU2004215672A1 (en)	2004-09-10
AU2004215677A1 (en)	2004-09-10
EP1599452B1 (de)	2007-06-20
RU2005129995A (ru)	2006-01-27
OA13034A (en)	2006-11-10
DK1599453T3 (da)	2009-08-24
UY28209A1 (es)	2004-09-30
TW200510352A (en)	2005-03-16
TW200500349A (en)	2005-01-01
NO20054396L (no)	2005-11-11
UY28210A1 (es)	2004-09-30
AR043433A1 (es)	2005-07-27
ZA200505768B (en)	2005-11-23
CN100439345C (zh)	2008-12-03
PL378130A1 (pl)	2006-03-06
ATE430738T1 (de)	2009-05-15
RU2005129992A (ru)	2006-02-10
US7365084B2 (en)	2008-04-29
ES2287700T3 (es)	2007-12-16
RS20050594A (en)	2007-12-31
TNSN05204A1 (en)	2007-06-11
MA27736A1 (fr)	2006-02-01
US20050101637A1 (en)	2005-05-12
MA27742A1 (fr)	2006-02-01
EP1599452A1 (de)	2005-11-30
ECSP055986A (es)	2006-01-16
US20080167354A1 (en)	2008-07-10
MA27737A1 (fr)	2006-02-01
KR20050106461A (ko)	2005-11-09
DE502004009690D1 (de)	2009-08-13

Publication	Publication Date	Title
PL378437A1 (pl)	2006-04-03	Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
HK1087103A1 (en)	2006-10-06	Anilinopyrazole derivatives useful for the treatment of diabetes
DZ2936A1 (fr)	2004-03-15	Composition nouvelle à libération modifiée pour letraitement du diabète.
NO20006630D0 (no)	2000-12-22	Farmasöytisk sammensetning for behandlingen av diabetes
HK1097258A1 (en)	2007-06-22	2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
NO20022087D0 (no)	2002-05-02	Fremgangsmåte for behandling av diabetes
AU2000276362A1 (en)	2002-01-21	Composition for the treatment of diabetes
AU2003279442A1 (en)	2004-04-23	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003296404A1 (en)	2004-08-10	Heterocyclic ppar modulators
AU2001292480A1 (en)	2002-04-08	Novel pyridazine compounds for the treatment of diabetes
EP1556085A4 (en)	2012-08-22	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
FR2848428B1 (fr)	2006-11-10	Composition cosmetique et procede pour le traitement des matieres keratiniques, comprenant un compose photodimerisable
PL375878A1 (pl)	2005-12-12	Pochodne N-podstawionego kwasu 1H-indolo-5-propionowego jako agoniści PPAR do leczenia cukrzycy
AU2003256650A1 (en)	2004-02-09	Substituted thiophene carboxamide compounds for the treatment of inflammation
AU2003223684A1 (en)	2003-11-10	Lxr modulators for the treatment of cardiovascular diseases
AU2003238046A1 (en)	2004-01-19	Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
AU2001247233A1 (en)	2001-09-03	Ppar gamma agonists for the treatment of liver inflammatory disorders
AU2003222667A1 (en)	2003-11-10	1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
AU2003266965A1 (en)	2004-02-25	Use of carboxamides for the treatment of tinnitus
NO20025883D0 (no)	2002-12-06	Tiazolidinonsalt for behandling av diabetes mellitus
AU2003273192A1 (en)	2003-12-19	Compounds and compositions for the treatment of diabetes and diabetes-related disorders
EP1177789A3 (en)	2003-01-29	Use of phytanic acid for the treatment of diabetes
AU2003255850A1 (en)	2004-02-09	Process for the preparation of modification i of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
AU2003260745A1 (en)	2004-03-19	Sulphonylamino derivatives for the treatment of alzheimer's disease
IL181010A0 (en)	2007-07-04	2-{3,'2- (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes

Legal Events

Date	Code	Title	Description
2011-12-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)